Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Momenta Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Momenta Pharmaceuticals shares (MNTA) are listed on the NASDAQ and all prices are listed in US Dollars. Momenta Pharmaceuticals employs 118 staff and has a trailing 12-month revenue of around USD$30.1 million.
|52-week range||USD$20.53 - USD$52.53|
|50-day moving average||USD$52.3753|
|200-day moving average||USD$37.7275|
|Wall St. target price||USD$52.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.441|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$30.1 million|
|Gross profit TTM||USD$-73,756,000|
|Return on assets TTM||-30.56%|
|Return on equity TTM||0%|
|Market capitalisation||USD$6.2 billion|
TTM: trailing 12 months
There are currently 5.4 million Momenta Pharmaceuticals shares held short by investors – that's known as Momenta Pharmaceuticals's "short interest". This figure is 23% up from 4.4 million last month.
There are a few different ways that this level of interest in shorting Momenta Pharmaceuticals shares can be evaluated.
Momenta Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Momenta Pharmaceuticals shares currently shorted divided by the average quantity of Momenta Pharmaceuticals shares traded daily (recently around 6.9 million). Momenta Pharmaceuticals's SIR currently stands at 0.79. In other words for every 100,000 Momenta Pharmaceuticals shares traded daily on the market, roughly 790 shares are currently held short.
However Momenta Pharmaceuticals's short interest can also be evaluated against the total number of Momenta Pharmaceuticals shares, or, against the total number of tradable Momenta Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Momenta Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Momenta Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0757% of the tradable shares (for every 100,000 tradable Momenta Pharmaceuticals shares, roughly 76 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Momenta Pharmaceuticals.
Find out more about how you can short Momenta Pharmaceuticals stock.
We're not expecting Momenta Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Momenta Pharmaceuticals's shares have ranged in value from as little as $20.53 up to $52.53. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Momenta Pharmaceuticals's is 1.7854. This would suggest that Momenta Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. As of September 30, 2020, Momenta Pharmaceuticals, Inc. operates as a subsidiary of Johnson & Johnson.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.